VGLL4 regulates the Wnt/β-catenin signaling pathway and acts as an oncogenic factor in acute myeloid leukemia.

IF 2 4区医学 Q3 HEMATOLOGY

Hematology Pub Date : 2026-12-31 Epub Date: 2026-04-15 DOI:10.1080/16078454.2026.2644710

Chen Zhou, Yujin Yin, Juan Gu, He Shen, Yuchu Yuan, Mingyan Wang

{"title":"VGLL4 regulates the Wnt/β-catenin signaling pathway and acts as an oncogenic factor in acute myeloid leukemia.","authors":"Chen Zhou, Yujin Yin, Juan Gu, He Shen, Yuchu Yuan, Mingyan Wang","doi":"10.1080/16078454.2026.2644710","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the expression, function, and underlying mechanism of VGLL4 in AML.Methods: Bioinformatic analysis of TCGA data by GEPIA website was performed. VGLL4 protein expression was analyzed by Western blot. We then performed functional assays (CCK-8, colony formation, and Transwell) to evaluate the effects of VGLL4 knockdown and overexpression on the proliferation, migration, and Matrigel matrix penetration ability of AML cell lines. Apoptosis was assessed by flow cytometry, and the expression of key Wnt/β-catenin pathway proteins was examined by Western blot.Results: Compared with controls, VGLL4 was significantly upregulated in AML. Functionally, VGLL4 knockdown potently suppressed AML cell proliferation, migration, and Matrigel matrix penetration ability, promoted apoptosis, and downregulated the expression of key pathway proteins, including β-catenin and GSK3β.Conclusion: VGLL4 acts as an oncogenic factor in AML, potentially through activating the Wnt/β-catenin pathway. Thus, we propose VGLL4 as a promising molecular target for AML therapy.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2644710"},"PeriodicalIF":2.0000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2026.2644710","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the expression, function, and underlying mechanism of VGLL4 in AML.

Methods: Bioinformatic analysis of TCGA data by GEPIA website was performed. VGLL4 protein expression was analyzed by Western blot. We then performed functional assays (CCK-8, colony formation, and Transwell) to evaluate the effects of VGLL4 knockdown and overexpression on the proliferation, migration, and Matrigel matrix penetration ability of AML cell lines. Apoptosis was assessed by flow cytometry, and the expression of key Wnt/β-catenin pathway proteins was examined by Western blot.

Results: Compared with controls, VGLL4 was significantly upregulated in AML. Functionally, VGLL4 knockdown potently suppressed AML cell proliferation, migration, and Matrigel matrix penetration ability, promoted apoptosis, and downregulated the expression of key pathway proteins, including β-catenin and GSK3β.

Conclusion: VGLL4 acts as an oncogenic factor in AML, potentially through activating the Wnt/β-catenin pathway. Thus, we propose VGLL4 as a promising molecular target for AML therapy.

查看原文本刊更多论文

VGLL4调节Wnt/β-catenin信号通路，在急性髓系白血病中作为致瘤因子。

目的：探讨VGLL4在AML中的表达、功能及机制。方法：通过GEPIA网站对TCGA数据进行生物信息学分析。Western blot检测VGLL4蛋白表达。然后，我们进行了功能测试（CCK-8、集落形成和Transwell），以评估VGLL4敲低和过表达对AML细胞系增殖、迁移和基质渗透能力的影响。流式细胞术检测细胞凋亡，Western blot检测Wnt/β-catenin通路关键蛋白的表达。结果：与对照组相比，VGLL4在AML中显著上调。功能上，VGLL4敲低可有效抑制AML细胞增殖、迁移和基质渗透能力，促进细胞凋亡，下调β-catenin和GSK3β等关键通路蛋白的表达。结论：VGLL4可能通过激活Wnt/β-catenin通路在AML中发挥致癌作用。因此，我们提出VGLL4作为AML治疗的一个有希望的分子靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology 医学-血液学

CiteScore

2.60

自引率

5.30%

发文量

140

审稿时长

3 months

期刊介绍： Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.